Seattle Genetics, Inc. (NASDAQ:SGEN) COO Eric Dobmeier sold 9,600 shares of the stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $57.80, for a total transaction of $554,880.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Eric Dobmeier also recently made the following trade(s):

  • On Friday, November 17th, Eric Dobmeier sold 35,000 shares of Seattle Genetics stock. The stock was sold at an average price of $58.25, for a total transaction of $2,038,750.00.
  • On Thursday, August 31st, Eric Dobmeier sold 25,000 shares of Seattle Genetics stock. The stock was sold at an average price of $52.24, for a total transaction of $1,306,000.00.
  • On Monday, August 28th, Eric Dobmeier sold 5,343 shares of Seattle Genetics stock. The stock was sold at an average price of $47.89, for a total transaction of $255,876.27.

Seattle Genetics, Inc. (NASDAQ:SGEN) opened at $59.79 on Friday. Seattle Genetics, Inc. has a 12 month low of $45.31 and a 12 month high of $73.91.

Seattle Genetics (NASDAQ:SGEN) last posted its earnings results on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.23. The firm had revenue of $135.29 million during the quarter, compared to the consensus estimate of $112.76 million. Seattle Genetics had a negative net margin of 26.53% and a negative return on equity of 32.41%. The company’s revenue was up 27.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.23) earnings per share. research analysts predict that Seattle Genetics, Inc. will post -0.93 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Eric Dobmeier Sells 9,600 Shares of Seattle Genetics, Inc. (SGEN) Stock” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://theolympiareport.com/2017/11/19/eric-dobmeier-sells-9600-shares-of-seattle-genetics-inc-sgen-stock.html.

Several equities research analysts have recently weighed in on the stock. TheStreet upgraded shares of Seattle Genetics from a “d” rating to a “c” rating in a research report on Thursday. Royal Bank Of Canada increased their price objective on shares of Seattle Genetics from $68.00 to $69.00 and gave the stock an “outperform” rating in a research report on Monday, November 13th. Cann initiated coverage on shares of Seattle Genetics in a report on Wednesday, November 8th. They issued a “hold” rating for the company. Zacks Investment Research upgraded shares of Seattle Genetics from a “hold” rating to a “buy” rating and set a $68.00 price target for the company in a report on Monday, November 6th. Finally, Morgan Stanley raised their price target on shares of Seattle Genetics from $64.00 to $69.00 and gave the stock an “overweight” rating in a report on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $63.53.

Several institutional investors and hedge funds have recently bought and sold shares of SGEN. Manning & Napier Advisors LLC purchased a new position in shares of Seattle Genetics in the third quarter worth about $140,098,000. Capital International Investors grew its stake in Seattle Genetics by 63.7% during the third quarter. Capital International Investors now owns 4,460,246 shares of the biotechnology company’s stock valued at $242,682,000 after acquiring an additional 1,735,657 shares in the last quarter. Janus Henderson Group PLC grew its stake in Seattle Genetics by 8,672.2% during the second quarter. Janus Henderson Group PLC now owns 704,673 shares of the biotechnology company’s stock valued at $36,460,000 after acquiring an additional 696,640 shares in the last quarter. Pictet Asset Management Ltd. grew its stake in Seattle Genetics by 79.3% during the third quarter. Pictet Asset Management Ltd. now owns 1,266,426 shares of the biotechnology company’s stock valued at $68,906,000 after acquiring an additional 560,110 shares in the last quarter. Finally, Capital Guardian Trust Co. grew its stake in Seattle Genetics by 82.2% during the third quarter. Capital Guardian Trust Co. now owns 1,064,300 shares of the biotechnology company’s stock valued at $57,909,000 after acquiring an additional 480,044 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.